Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$44 Mln
P/E Ratio
--
P/B Ratio
0.87
Industry P/E
--
Debt to Equity
--
ROE
-0.81 %
ROCE
-80.82 %
Div. Yield
0 %
Book Value
17.49
EPS
-11.83
CFO
$-190.94 Mln
EBITDA
$-199.94 Mln
Net Profit
$-294.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
| -70.47 | 6.12 | -55.70 | -62.73 | -40.91 | -57.30 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
| 10.42 | -17.80 | -53.27 | -94.12 | 355.24 | -93.51 | -19.81 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and... autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Read more
CEO, President & Chairman
Dr. Paul A. Wagner Ph.D.
CEO, President & Chairman
Dr. Paul A. Wagner Ph.D.
Headquarters
Dallas, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Forte Biosciences Inc (FBRX) stood at $ 62 Mln as on 31-Dec-24
The share price of Forte Biosciences Inc (FBRX) is $6.71 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Forte Biosciences Inc (FBRX) has given a return of -40.91% in the last 3 years.
Forte Biosciences Inc (FBRX) has a market capitalisation of $ 44 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Forte Biosciences Inc (FBRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Forte Biosciences Inc (FBRX) and enter the required number of quantities and click on buy to purchase the shares of Forte Biosciences Inc (FBRX).
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
The CEO & director of Dr. Paul A. Wagner Ph.D.. is Forte Biosciences Inc (FBRX), and CFO & Sr. VP is Dr. Paul A. Wagner Ph.D..
There is no promoter pledging in Forte Biosciences Inc (FBRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Forte Biosciences Inc. (FBRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-80.82
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Forte Biosciences Inc (FBRX) was $0 Mln.
$-0.25
(
